Rights & Society
New Lung Cancer Treatment Recommended by EMA
The European Medicines Agency (EMA) has recommended granting marketing authorization for Imdylltra (tarlatamab) for relapsed extensive-stage small cell lung cancer. The new treatment offers a monotherapy option for adults with this specific type of cancer. EMA's recommendation is a significant step towards providing patients with new therapeutic options. The European Commission will now review EMA's recommendation and decide whether to grant marketing authorization.
EMA recommends new lung cancer treatment, offering hope for patients in the EU.